Search Bar & Filters
Found 1696 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating how awareness and personal perception influence the placebo effect during exercise. This study involves healthy adults participating in a cycling session where perceived fatigue is the main outcome. The research compares three groups active placebo, passive placebo, and control, focusing on how different presentations of a drink affect feelings of fatigue and emotional state during exercise. Participants attend a gym session including a 10-minute warm-up and a 10-minute intense cycling test on a cycle ergometer. They wear a heart rate monitor to track heart and respiratory rates throughout. Each group receives a ginger-flavored drink described differently one group can decide when to consume an energizing drink, another is told to consume it before continuing, and the control group receives a mineral drink before exercise. No actual energizing substances are in the drinks. Before and after exercise, participants complete online questionnaires assessing exertion and emotions. Researchers record cycling data such as distance and speed. After the session, a perceived control questionnaire is given, and participants are debriefed about the placebo nature of the drinks. The entire process, including assessments and exercise, takes about two hours per participant.
Actively Recruiting
Healthy Volunteer
This research aims to evaluate whether creating dedicated HIV teams in hospitals across ten European countries can increase HIV testing rates among patients showing signs of HIV-related conditions. The study uses a stepped-wedge design, where hospitals switch from routine care to the new intervention in sequence. This approach compares outcomes before and after the teams are in place, helping to understand the impact of the intervention across various locations and medical specialties. The intervention involves establishing local HIV teams led by specialists and supported by nurses and data experts. These teams identify patients needing HIV tests through electronic health records, provide feedback to doctors to encourage testing, offer education to healthcare staff about HIV, reduce stigma, and improve connections to prevention and care services. This program integrates smoothly into regular hospital routines and aims to close gaps in HIV diagnosis. Participants HIV testing rates will be monitored by reviewing records before and after the intervention. Researchers will also assess new HIV diagnoses, changes in testing patterns by country and specialty, and healthcare professionals knowledge and attitudes toward HIV. The study includes ongoing evaluation of how well the teams operate, resource use, and cost-effectiveness. Data collection extends up to several years to observe long-term effects, with continuous monitoring of care access and prevention services.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.
Actively Recruiting
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
Actively Recruiting
Researchers are studying patients with Luminal A and estrogen receptor-positive ER-positive lobular breast cancer to evaluate a new imaging method. This study aims to assess the use of hybrid PETMRI combined with a radiolabeled form of estrogen called 16-alpha-18F-fluoro-17-beta-estradiol FES for accurate, non-invasive staging of these breast cancers. The study focuses on comparing this imaging techniques ability to detect cancer spread in axillary lymph nodes with the results from axillary surgery. Participants will undergo a single cohort study where they receive primary surgery as their first treatment. Before surgery, they will have an FES PETMRI scan using the radiotracer FES to capture detailed images of their cancer. Selected patients with heterogeneous tumors on imaging will also have further analysis through pathology, imaging, genomic, and radiomic studies to explore tumor characteristics. Throughout the study, participants will be monitored for the sensitivity of the FES PETMRI in detecting axillary lymph node metastases. Researchers will collect imaging data before surgery and compare it with surgical findings. The study involves no masking or placebo and will follow patients from enrollment until after surgery to gather diagnostic performance data. The total study period extends until 2029, with primary outcome assessment planned around 50 days after imaging.
Actively Recruiting
Researchers are evaluating a treatment approach for patients with localized prostate cancer who are candidates for stereotactic radiotherapy targeting the prostate and seminal vesicles. This interventional, prospective, non-randomized clinical trial aims to assess the safety and effectiveness of a single high-dose radiation treatment using a urethral-sparing technique similar to high-dose-rate HDR brachytherapy. The study focuses on acute and late toxicity, biochemical control, survival outcomes, and quality of life over several years. The treatment involves delivering a single 24 Gy fraction of stereotactic body radiotherapy SBRT to the prostate and seminal vesicles, sparing the urethra to minimize side effects. Before treatment, patients undergo staging exams including PSMA PET-CT scans and uroflowmetry tests. The procedure includes fiducial implantation, CT simulation, and magnetic resonance imaging on the same day as treatment. Androgen deprivation therapy ADT may be prescribed according to disease risk. Short-term cortisone and alpha-blocker medications are given as preventive measures. Participants will be followed for up to five years with scheduled visits at 1, 3, 6, 12, 18, 24, 36, 48, and 60 months. Assessments include blood tests for prostate-specific antigen PSA and testosterone, imaging as needed, and quality of life questionnaires covering general health, urinary symptoms, erectile function, and prostate cancer-specific concerns. The primary outcome is acute toxicity one month after treatment, with additional monitoring of biochemical relapse, disease control, survival, and treatment-related side effects.
Actively Recruiting
Researchers are studying degenerative disc disease by defining the genetic profiles of primary human cells from different parts of the spinal disc, including the nucleus pulposus, annulus fibrosus, and cartilaginous endplate. The goal is to use this information as a reference to evaluate a lab-created 3D spinal unit model made through bioprinting. This study will assess how well the bioprinted model mimics the natural disc environment by comparing gene activity between native cells and those in the 3D construct. The study involves developing a human-origin in vitro model that integrates key spinal components using advanced bioprinting technology. Researchers will analyze gene expression in tissue samples from patients undergoing spinal surgery and compare these with cells recovered from the bioprinted model. This comparison aims to measure the accuracy and biological relevance of the 3D spinal unit model. Participants will be adults aged 30 to 70 who have degenerative disc disease with specific MRI grading and require spinal surgery. The main measurement is discovering tissue-specific molecular markers in intervertebral disc cells over a 24-month period from enrollment through data analysis. Participants provide consent and tissue samples during surgery, with no additional treatments involved. The study is observational, focusing on collecting and analyzing biological data to improve understanding of spinal disc biology.
Actively Recruiting
Researchers are evaluating a new radiation therapy approach for breast cancer patients who are young or have unfavorable tumor characteristics. This study compares a shorter, more intense radiation schedule against the current standard treatment to see if it is not worse in terms of effectiveness. Participants include patients with specific breast cancer types and stages, treated after breast-conserving surgery. Participants are randomly assigned to one of two groups. The first group receives whole breast irradiation with a total dose of 26 Gy over 5 sessions, including a simultaneous higher dose boost to the tumor area. The second group receives the standard treatment with a total dose of 40.05 Gy over 15 sessions, also with a simultaneous boost to the tumor bed. Advanced radiation techniques are used to target the treatment area while protecting nearby organs. During the study, participants undergo regular clinical assessments to monitor tumor control and side effects over five years. Researchers evaluate local relapse-free survival as the main outcome, along with various measures of toxicity, tumor recurrence, survival rates, quality of life, and treatment impact. The study involves follow-up visits and tests to assess both short-term and long-term effects of the treatments.
Actively Recruiting
Researchers are investigating a new treatment approach for metastatic colorectal cancer mCRC that combines several chemotherapy drugs with a drug that blocks blood vessel growth called bevacizumab. This study focuses on patients whose tumors have a specific genetic change called MGMT silencing and who have a stable microsatellite status. The goal is to test the safety and appropriate dose of this combination, as previous research shows that combining these drugs may overcome resistance seen with single treatments. The treatment includes 5-fluorouracil, leucovorin, irinotecan, temozolomide, and bevacizumab. It starts with an induction phase of four 28-day cycles given every two weeks, including continuous infusion of 5-fluorouracil and intravenous infusions of the other drugs. Temozolomide is taken orally in increasing doses over five days every 28 days. After the induction, patients without disease progression continue with maintenance treatment using 5-fluorouracil, leucovorin, bevacizumab, and oral temozolomide. The study uses a dose-escalation design to find the maximum tolerated dose or recommended dose for further testing. Participants will have tumor assessments at the start and every 8 weeks to monitor disease status and side effects. Safety, response to treatment, and quality of life are regularly evaluated using clinical exams and questionnaires. The study will continue treatment until the disease progresses, unacceptable side effects occur, or participants choose to stop. The phase 1b part determined the recommended dose of temozolomide, and the phase 2 part is ongoing to assess treatment effectiveness over two years.
Actively Recruiting
Gastroenteropancreatic neuroendocrine tumours GEP-NETs are a diverse group of tumors arising from endocrine cells in the digestive tract. Researchers are evaluating the use of 68Ga-DOTATOC PET imaging, combined with MRI or CT scans, to improve diagnosis and prognosis for patients with GEP-NETs. This study focuses on assessing the accuracy and predictive value of these imaging techniques over a period of 10 years. Patients who qualify will undergo 68Ga-DOTATOC PET as part of their standard diagnostic process. This PET scan may be performed with MRI or CT, with PETMRI conducted on a 3.0T time-of-flight scanner approximately 60 minutes after injection of the tracer. The study will include patients during their regular clinical evaluation without additional experimental treatments. Participants will be monitored through their imaging results collected during routine care. The main outcome measured is the diagnostic accuracy of the imaging over 10 years. The study aims to gather important information on how these imaging methods can predict disease progression and mortality while minimizing radiation exposure, especially with the use of PETMRI. Participants give informed consent and receive imaging based on clinical need throughout their follow-up.
1-10 of 1,696
1